Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Mike Khouw Sees Unusual Options Activity In Celgene
Watch These 7 Huge Call Purchases In Friday Trade
Game Plan For The Week - Cramer's Mad Money (9/23/16) (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $91.00 to $94.00.

Jefferies noted, “CELG announced Abraxane met its overall survival primary endpoint in its Phase 3 pancreatic cancer study. We have long considered this indication to be risky and upside to our valuation. Adding pancreatic cancer to our valuation raises our price target from $91 to $94.”

Celgene Corporation closed on Friday at $71.50.

Latest Ratings for CELG

DateFirmActionFromTo
Aug 2016BTIG ResearchUpgradesNeutralBuy
Jul 2016StifelInitiates Coverage onBuy
Jun 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!